Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Classical hematology 2Genitourinary 1

Conditions

Anemia 3Neoplasms 2Renal Insufficiency, Chronic 1Kidney Failure, Chronic 1

Interventions

Epoetin Alfa 25Darbepoetin alfa 17apixaban 9Rivaroxaban 9Dalteparin 7Heparin, Low-Molecular-Weight 6Surveys and Questionnaires 5Meropenem 5fludarabine phosphate 4Vancomycin 4Tinzaparin 4Enoxaparin 4Cyclosporine 4Cefepime 4ferric carboxymaltose 3edoxaban 3Whole-Body Irradiation 3Peripheral Blood Stem Cell Transplantation 3Mycophenolic Acid 3Ceftazidime 3Carboplatin 3Busulfan 3Antilymphocyte Serum 3Amikacin 3romiplostim 2peginesatide 2hematide 2fludarabine 2epoetin beta 2bemiparin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasms × hematide × Classical hematology × Clear all
NCT00097747 2012-12-21

Safety and Pharmacokinetics of Single Intravenous Doses of Peginesatide in Healthy Volunteers

Affymax

Phase 1 Completed
28 enrolled
Classical hematologyGenitourinary

Anemia, Kidney Failure, Chronic, Neoplasms, Renal Insufficiency, Chronic

NCT00272662 2012-12-21

Study of Subcutaneously Administered Peginesatide in Anemic Cancer Patients Receiving Chemotherapy

Affymax

Phase 2 Completed
60 enrolled
Classical hematology

Anemia, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡